February 18, 2015Journal of Clinical Oncology

First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis

View Full Paper

Ask AI

Bookmark

Authors

DGDaniel A. GoldsteinBoston University QCQiushi ChenShanghaiTech University TATurgay AyerGeorgia Institute of Technology

Abstract

Bevacizumab provides minimal incremental benefit at high incremental cost per QALY in both the first- and second-line settings of metastatic colorectal cancer treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Goldstein et al. (2015) studied this question.

synapsesocial.com/papers/69d6f69ca0177bf533ed96e1 https://doi.org/10.1200/jco.2014.58.4904

View Full Paper

Ask AI

Bookmark

Abstract

Bevacizumab provides minimal incremental benefit at high incremental cost per QALY in both the first- and second-line settings of metastatic colorectal cancer treatment.

First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis

Abstract

Discussion

Cite This Study

First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis

Abstract

Discussion

Cite This Study

Also Consider

Also Consider